选择性向PDE4B/D亚型的下一代PDE4抑制剂:叙述性审查
Andrew Blauvelt1, Richard G Langley2, Kenneth B Gordon3
1Oregon Medical Research Center, 9495 SW Locust Street, Suite G, Portland, OR, 97223, USA. ablauvelt@oregonmedicalresearch.com.
Dermatology and therapy
|November 4, 2023
概括
新的选择性化酶4 (PDE4) 抑制剂针对PDE4B/D提供了一个有前途的口服治疗炎症性皮肤疾病. 本综述总结了新兴的PDE4抑制剂,并将它们的选择性与现有的选择性进行比较.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 局部皮质类固醇是轻度至中度炎症性皮肤疾病的标准,但有局限性.
- 针对特定细胞因子 (例如IL-17,IL-23,IL-13) 的生物药物已经出现,但许多患者更喜欢口服治疗.
- 固酶4 (PDE4) 抑制剂已被批准用于炎症性皮肤疾病,可提供口服和局部配方.
研究的目的:
- 对炎症性皮肤疾病的新兴选择性化酶4B/D (PDE4B/D) 抑制剂进行审查.
- 为了比较新一代PDE4抑制剂的选择性概况与目前批准的,选择性较低的PDE4抑制剂.
主要方法:
- 新兴选择性PDE4B/D抑制剂的文献综述.
- 对PDE4抑制剂选择性的比较分析.
主要成果:
- 一个新兴的选择性PDE4B/D抑制剂类别正在临床开发中.
- 在新的和现有的PDE4抑制剂之间存在选择性的差异.
结论:
- 选择性PDE4B/D抑制剂代表了炎症性皮肤疾病的新疗法.
- 了解PDE4抑制剂的选择性对于优化治疗结果至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
163
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
163
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
847
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
847
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
535
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
535
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
172
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172


